# Glycogen Storage Diseases: Diagnosis and Dietary Management

## Introduction

Glycogen storage diseases (GSDs) are a group of inherited metabolic disorders caused by defects in enzymes or transporters involved in glycogen synthesis or breakdown. There are over 15 recognized types, with a combined incidence of approximately 1 in 20,000-40,000 live births. Clinical presentations range from severe neonatal hypoglycemia to adult-onset myopathy, depending on the enzyme affected and the tissues involved.

## Classification and Key Types

### Hepatic GSDs (Primarily Liver Involvement)

GSD Ia (von Gierke disease) results from glucose-6-phosphatase deficiency and presents with severe fasting hypoglycemia, hepatomegaly, lactic acidosis, hyperuricemia, and hyperlipidemia. GSD Ib involves glucose-6-phosphate translocase deficiency and produces a similar phenotype to Ia with the addition of neutropenia and inflammatory bowel disease. GSD III (Cori/Forbes disease) results from debranching enzyme deficiency, causing hepatomegaly, hypoglycemia, myopathy, and cardiomyopathy. GSD VI (Hers) and GSD IX involve phosphorylase and phosphorylase kinase deficiencies respectively, producing milder hepatic phenotypes.

### Muscle GSDs (Primarily Skeletal Muscle)

GSD V (McArdle disease) results from myophosphorylase deficiency, presenting with exercise intolerance, myoglobinuria, and the characteristic second wind phenomenon. GSD VII (Tarui disease) involves phosphofructokinase deficiency with exercise intolerance and hemolytic anemia.

### Generalized GSDs

GSD II (Pompe disease) results from acid alpha-glucosidase deficiency and is classified as a lysosomal storage disorder. It presents with infantile and late-onset forms characterized by cardiomyopathy and progressive myopathy.

| GSD Type | Enzyme Deficiency | Gene | Primary Tissue | Key Features | Dietary Approach |
|---|---|---|---|---|---|
| Ia (von Gierke) | Glucose-6-phosphatase | G6PC | Liver | Severe fasting hypoglycemia, hepatomegaly, lactic acidosis, hyperlipidemia | Frequent feeds; uncooked cornstarch; restrict fructose/galactose |
| Ib | G6P translocase | SLC37A4 | Liver | As Ia + neutropenia, IBD | As Ia + G-CSF for neutropenia |
| III (Cori/Forbes) | Debranching enzyme | AGL | Liver, muscle | Hepatomegaly, hypoglycemia, myopathy, cardiomyopathy | High-protein diet; cornstarch |
| V (McArdle) | Myophosphorylase | PYGM | Muscle | Exercise intolerance, myoglobinuria, second wind | Pre-exercise carbohydrate; graded exercise |
| VI (Hers) | Phosphorylase | PYGL | Liver | Mild hepatomegaly, mild hypoglycemia | Cornstarch if needed; often mild |
| IX | Phosphorylase kinase | PHKA2, PHKB, others | Liver | Mild hepatomegaly; often self-resolving | Cornstarch if symptomatic |
| II (Pompe) | Acid alpha-glucosidase | GAA | Generalized (lysosomal) | Cardiomyopathy (infantile); progressive myopathy | ERT (not dietary) |

## Pathophysiology

Defective glycogen metabolism leads to abnormal glycogen accumulation in affected tissues. Hepatic forms cause inability to maintain euglycemia during fasting due to impaired glycogenolysis and/or gluconeogenesis. Muscle forms result in energy failure during exercise with inability to mobilize glycogen for ATP production. Secondary metabolic derangements include lactic acidosis, hyperuricemia, and hyperlipidemia.

## Diagnostic Approach

### Clinical Evaluation

Key elements include age of presentation, fasting tolerance, hepatomegaly, and growth parameters. Exercise-induced symptoms such as cramps, myoglobinuria, and second wind phenomenon point to muscle GSDs.

### Biochemical Testing

Fasting glucose and lactate are critical for hepatic GSDs. Uric acid, triglycerides, and cholesterol are commonly elevated in GSD I. Creatine kinase (CK) is elevated in muscle GSDs. The ischemic forearm exercise test (flat lactate with elevated ammonia suggesting GSD V) has been largely replaced by genetic testing.

### Enzyme Assays

Enzyme activity can be measured in liver biopsy, leukocytes, erythrocytes, or muscle biopsy depending on the GSD type. Dried blood spot screening is available for Pompe disease.

### Molecular Testing

Targeted gene sequencing or multi-gene GSD panels are now first-line in many centers. Common mutations include p.R83C in G6PC (GSD Ia) and p.R50X in PYGM (GSD V).

## Dietary Management: Hepatic GSDs

### GSD Type I

Management requires frequent feedings with avoidance of fasting (every 2-4 hours in infants). Uncooked cornstarch (1.5-2.5 g/kg every 4-6 hours) provides slow-release glucose. Modified cornstarch (Glycosade) allows extended overnight fasting of up to 8-10 hours. Fructose, sucrose, galactose, and lactose must be restricted because these sugars cannot be converted to free glucose and exacerbate lactic acidosis. Lipid-lowering dietary modifications are employed, with fibrates or fish oil considered for persistent hypertriglyceridemia.

### GSD Types III, VI, IX

A high-protein diet (25-30% of calories) is recommended because protein serves as a gluconeogenic substrate. Moderate complex carbohydrate intake with cornstarch as needed maintains fasting tolerance. Management is less restrictive than GSD I since gluconeogenesis remains intact.

### Nocturnal Management

Continuous gastrostomy feeds are used in infants and young children, with transition to cornstarch-based regimens as children mature.

## Management of Muscle GSDs

### GSD V (McArdle Disease)

Moderate-intensity aerobic conditioning improves exercise capacity. Pre-exercise oral sucrose loading provides an alternative substrate. High-intensity isometric exercise should be avoided. Unlike hepatic GSDs, no dietary fructose or galactose restriction is needed.

### GSD VII

Similar exercise precautions apply, though sucrose loading is contraindicated as it worsens hemolysis.

## Monitoring and Long-Term Complications

### GSD Type I

Hepatic adenomas carry risk of malignant transformation and require monitoring with serial ultrasound and alpha-fetoprotein. Renal complications include proteinuria, nephrocalcinosis, and renal failure, with ACE inhibitors used for microalbuminuria. Osteoporosis requires monitoring of bone density with adequate calcium and vitamin D. Gout is managed with allopurinol for hyperuricemia. Growth and pubertal delay improve with optimal metabolic control.

### GSD Type III

Cardiomyopathy requires regular echocardiography. Progressive myopathy develops in adulthood. Liver fibrosis and cirrhosis are less common but recognized complications.

## Emerging Therapies

Enzyme replacement therapy for Pompe disease (alglucosidase alfa, avalglucosidase alfa) is established. AAV-based gene therapy clinical trials are ongoing for GSD Ia and GSD III. mRNA therapy is investigational for GSD Ia. Empagliflozin (SGLT2 inhibitor) is under investigation for glycogen-related nephropathy in GSD I.

## Clinical Pearls

GSD Ia requires lifelong dietary management with cornstarch and strict avoidance of fructose, sucrose, galactose, and lactose to prevent metabolic crises. The second wind phenomenon in GSD V is pathognomonic and results from increased blood flow and fatty acid oxidation during sustained exercise. Molecular testing has largely replaced invasive tissue biopsies for diagnosis of most GSD types. Hepatic adenomas in GSD I require surveillance due to risk of hepatocellular carcinoma, particularly in poorly controlled patients.

## References

1. Kishnani PS, Austin SL, Abdenur JE, et al. Diagnosis and management of glycogen storage disease type I: a practice guideline. *Genet Med*. 2014;16(11):e1.
2. Hicks J, Wartchow E, Mierau G. Glycogen storage diseases: a brief review and update on clinical features, genetic abnormalities, pathologic features, and treatment. *Ultrastruct Pathol*. 2011;35(5):183-196.
3. Goldstein JL, Austin SL, Boyette K, et al. Molecular analysis of the AGL gene: identification of 25 novel mutations and evidence of genetic heterogeneity in patients with glycogen storage disease type III. *Genet Med*. 2010;12(7):424-430.
4. Derks TGJ, Rodriguez-Buritica DF, Ahmad A, et al. Glycogen storage disease type Ia: current management options, burden and unmet needs. *Nutrients*. 2021;13(11):3828.